DOCM Stock Overview
Operates e-commerce pharmacies and a wholesale business for medical and pharmaceutical products in Switzerland and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
DocMorris AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 20.96 |
| 52 Week High | CHF 101.60 |
| 52 Week Low | CHF 19.34 |
| Beta | 1.4 |
| 1 Month Change | -29.33% |
| 3 Month Change | -44.23% |
| 1 Year Change | -71.58% |
| 3 Year Change | -91.10% |
| 5 Year Change | -80.66% |
| Change since IPO | -86.89% |
Recent News & Updates
It's Down 30% But DocMorris AG (VTX:DOCM) Could Be Riskier Than It Looks
Dec 10
DocMorris AG's (VTX:DOCM) Subdued P/S Might Signal An Opportunity
Oct 25Does DocMorris (VTX:DOCM) Have A Healthy Balance Sheet?
Sep 22Recent updates
It's Down 30% But DocMorris AG (VTX:DOCM) Could Be Riskier Than It Looks
Dec 10DocMorris AG's (VTX:DOCM) Subdued P/S Might Signal An Opportunity
Oct 25Does DocMorris (VTX:DOCM) Have A Healthy Balance Sheet?
Sep 22Would Zur Rose Group (VTX:ROSE) Be Better Off With Less Debt?
Sep 07We Think Zur Rose Group (VTX:ROSE) Has A Fair Chunk Of Debt
Dec 05We Think Zur Rose Group (VTX:ROSE) Has A Fair Chunk Of Debt
Aug 22Is Zur Rose Group (VTX:ROSE) Using Too Much Debt?
Apr 19Earnings Update: Zur Rose Group AG (VTX:ROSE) Just Reported And Analysts Are Trimming Their Forecasts
Mar 22Some Zur Rose Group AG (VTX:ROSE) Analysts Just Made A Major Cut To Next Year's Estimates
Mar 20What Kind Of Investors Own Most Of Zur Rose Group AG (VTX:ROSE)?
Feb 23Is Zur Rose Group's (VTX:ROSE) Share Price Gain Of 210% Well Earned?
Jan 19Zur Rose Group AG (VTX:ROSE) Is Expected To Breakeven In The Near Future
Dec 15Shareholder Returns
| DOCM | CH Consumer Retailing | CH Market | |
|---|---|---|---|
| 7D | 6.0% | -0.004% | 0.6% |
| 1Y | -71.6% | -1.3% | 2.3% |
Return vs Industry: DOCM underperformed the Swiss Consumer Retailing industry which returned -1.3% over the past year.
Return vs Market: DOCM underperformed the Swiss Market which returned 2.3% over the past year.
Price Volatility
| DOCM volatility | |
|---|---|
| DOCM Average Weekly Movement | 9.3% |
| Consumer Retailing Industry Average Movement | 4.0% |
| Market Average Movement | 3.3% |
| 10% most volatile stocks in CH Market | 7.5% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: DOCM's share price has been volatile over the past 3 months compared to the Swiss market.
Volatility Over Time: DOCM's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swiss stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 1,453 | Walter Hess | corporate.docmorris.com/en |
DocMorris AG operates e-commerce pharmacies and a wholesale business for medical and pharmaceutical products in Switzerland and internationally. The company offers prescription and over-the-counter medicines, consumer health products, beauty and personal care products, nutritional supplements, painkillers, and first aid products. It also provides professional health care services.
DocMorris AG Fundamentals Summary
| DOCM fundamental statistics | |
|---|---|
| Market cap | CHF 270.32m |
| Earnings (TTM) | -CHF 97.26m |
| Revenue (TTM) | CHF 1.00b |
0.3x
P/S Ratio-2.8x
P/E RatioIs DOCM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DOCM income statement (TTM) | |
|---|---|
| Revenue | CHF 1.00b |
| Cost of Revenue | CHF 792.13m |
| Gross Profit | CHF 210.66m |
| Other Expenses | CHF 307.92m |
| Earnings | -CHF 97.26m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Mar 13, 2025
| Earnings per share (EPS) | -7.54 |
| Gross Margin | 21.01% |
| Net Profit Margin | -9.70% |
| Debt/Equity Ratio | 93.8% |
How did DOCM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 22:09 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
DocMorris AG is covered by 21 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Volker Bosse | Baader Helvea Equity Research |
| Gerhard Orgonas | Berenberg |
| Ashley Wallace | BofA Global Research |